Mesoblast WKN: A0DNPW ISIN: AU000000MSB8 Kürzel: LWB Branche: Gesundheit, Biotechnologie
|
|
Themen zum Wert | ||
|---|---|---|---|
| 1 | MESOBLAST Hauptdiskussion |
Kursdetails
| Geld (bid) | 0,0000 (0) |
|---|---|
| Brief (ask/offer) | 0,0000 (0) |
| Spread | - |
| Geh. Stück | 4.000 |
| Eröffnung | 0,5500 |
| Vortag | 0,5098 |
| Tageshoch | 0,6051 |
| Tagestief | 0,5500 |
| 52W Hoch | 1,0000 |
| 52W Tief | 0,1000 |
Tagesvolumen
| in EUR gehandelt | 37.115 Stk |
|---|---|
| in USD gehandelt | 4.000 Stk |
| in CHF gehandelt | 2.000 Stk |
| in AUD gehandelt | 0 Stk |
| Gesamt | 43.115 Stk |
Partner-News
AnzeigeGestern 18:00 Uhr • Partner • Societe Generale
Gestern 16:45 Uhr • Partner • Societe Generale
Gestern 16:00 Uhr • Partner • onemarkets Blog
Gestern 15:09 Uhr • Partner • Societe Generale
Gestern 15:00 Uhr • Partner • BNP Paribas
Aktien-News
Gestern 23:59 Uhr • Meldungen • IRW-News
Gestern 23:09 Uhr • Artikel • dpa-AFX
Gestern 22:49 Uhr • Artikel • dpa-AFX
Gestern 22:30 Uhr • Artikel • dpa-AFX
Gestern 21:27 Uhr • Artikel • dpa-AFX
Geld/Brief Kurse
Neu laden| Börse | Geld | Vol. | Brief | Vol. | Zeit | Vol. ges. | Kurs |
|---|---|---|---|---|---|---|---|
| L&S Exchange | 0,5700 | 898 Stk | 0,6300 | 898 Stk | 1713906045 23. Apr | 0,6000 EUR | |
| Nasdaq OTC | 1713907200 23. Apr | 4.000 Stk | 0,6051 USD | ||||
| Baader Bank | 0,5750 | 5.178 Stk | 0,5850 | 5.178 Stk | 1713881975 23. Apr | 0,5800 EUR | |
| Frankfurt | 0,5700 | 2.000 Stk | 0,6300 | 2.000 Stk | 1713878941 23. Apr | 0,5200 EUR | |
| Tradegate | 0,5750 | 3.761 Stk | 0,6050 | 3.522 Stk | 1713903982 23. Apr | 23.523 Stk | 0,5900 EUR |
| Lang & Schwarz | 0,5700 | 898 Stk | 0,6300 | 898 Stk | 1713906045 23. Apr | 10.000 Stk | 0,6000 EUR |
| TTMzero RT | 1713881843 23. Apr | 0,5900 EUR | |||||
| Berlin | 0,5450 | 10.800 Stk | 0,6350 | 9.900 Stk | 1713901563 23. Apr | 0,5900 EUR | |
| Hamburg | 0,5700 | 2.000 Stk | 0,6300 | 2.000 Stk | 1713852040 23. Apr | 0,5150 EUR | |
| München | 0,5750 | 3.761 Stk | 0,6050 | 3.522 Stk | 1713852013 23. Apr | 0,5350 EUR | |
| Stuttgart | 0,5750 | 20.100 Stk | 0,6050 | 20.100 Stk | 1713775005 22. Apr | 0,4660 EUR | |
| BX Swiss | 0,4920 | 22.273 Stk | 0,6140 | 22.273 Stk | 1713196800 15. Apr | 2.000 Stk | 0,5010 CHF |
| Sydney | 1713852656 23. Apr | 0,9000 AUD | |||||
| Gettex | 0,5750 | 5.178 Stk | 0,5850 | 5.178 Stk | 1713901462 23. Apr | 3.592 Stk | 0,5750 EUR | ges. 43.115 Stk |
Börsennotierung
| Marktkapitalisierung in EUR |
|---|
| 353,1 Mio. |
| Anzahl der Aktien |
| 737,1 Mio. |
Termine
| 30.05.2024 | Quartalsmitteilung |
|---|---|
| 29.07.2024 | Quartalsmitteilung |
| 02/25 | Quartalsmitteilung |
Grundlegende Daten zur MESOBLAST Aktie
| Finanzdaten | 2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e |
|---|---|---|---|---|---|---|---|
| KUV | 66,68 | 195,71 | 60,94 | 113,97 | - | - | - |
| Ergebnis je Aktie (bereinigt) | -0,13 | -0,15 | -0,12 | -0,10 | -0,61 | - | - |
| Cashflow | -56,4 Mio. | -0,1 Mrd. | -65,8 Mio. | -63,3 Mio. | - | - | - |
| Eigenkapitalquote | 74,88 % | 78,07 % | 75,07 % | 74,97 % | - | - | - |
| Verschuldungsgrad | 33,55 | 28,09 | 33,22 | 33,39 | - | - | - |
| EBIT | -79,1 Mio. | -0,1 Mrd. | -81,0 Mio. | -69,1 Mio. | - | - | - |
| Fundamentaldaten | 2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e |
| KCV | -33,34 | -12,23 | -6,77 | -14,25 | - | - | - |
| Kurs-Gewinn-Verhältnis (KGV) | -25,65 | -13,05 | -5,08 | -11,40 | -1,31 | - | - |
| Bilanzdaten | 2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e |
| Umsatzerlöse | 32,2 Mio. | 7,5 Mio. | 10,2 Mio. | 7,5 Mio. | - | - | - |
| Ergebnis vor Steuern | -87,4 Mio. | -99,6 Mio. | -91,6 Mio. | -82,1 Mio. | - | - | - |
| Steuern | -9,4 Mio. | -0,8 Mio. | -0,2 Mio. | -0,2 Mio. | - | - | - |
Info MESOBLAST Aktie
Mesoblast
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.